Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease.

Lukas HartlKatharina HaslingerMartin AngererGeorg SemmlerMathias Schneeweiss-GleixnerMathias Jachs Benedikt Simbrunner David Josef Maria BauerErnst EigenbauerRobert StrasslMonika BreuerOliver KimbergerDaniel LaxarKatharina LampichlerEmina HalilbasicAlbert Friedrich StättermayerAhmed Ba-SsalamahMattias Mandorfer Bernhard Scheiner Thomas ReibergerMichael Trauner

Published in: Hepatology (Baltimore, Md.) (2022)

About 20% of patients with CLD develop progressive cholestasis after SARS-CoV-2 infection. Patients with NAFLD/NASH and metabolic risk factors are at particular risk for developing cholestatic liver failure and/or SSC after COVID-19.

Keyphrases

liver failure
coronavirus disease
risk factors
sars cov
multiple sclerosis
drug induced
respiratory syndrome coronavirus
liver injury
hepatitis b virus
liver fibrosis